Molecular Partners highlights bispecific Radio-DARPins at Gordon Research Conference
PUBT · 1d ago
Share
Listen to the news
- Molecular Partners highlighted development of bispecific Radio-DARPins designed to engage multiple tumor targets, aiming to improve precision in radioligand therapy.
- It said multispecific formats could address tumor heterogeneity, building on its mono-targeting Radio-DARPin programs.
- Lead candidate MP0712, targeting DLL3, is in a multicenter US Phase 1/2a trial with Orano Med.
- Second candidate MP0726, targeting mesothelin, is expected to reach first human imaging this year.
- It expects to announce a third Radio-DARPin program in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved